1. Home
  2. DLNG vs KPTI Comparison

DLNG vs KPTI Comparison

Compare DLNG & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Dynagas LNG Partners LP

DLNG

Dynagas LNG Partners LP

HOLD

Current Price

$3.87

Market Cap

139.0M

ML Signal

HOLD

Logo Karyopharm Therapeutics Inc.

KPTI

Karyopharm Therapeutics Inc.

HOLD

Current Price

$6.30

Market Cap

148.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DLNG
KPTI
Founded
2013
2008
Country
Greece
United States
Employees
N/A
N/A
Industry
Marine Transportation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
139.0M
148.0M
IPO Year
2013
2013

Fundamental Metrics

Financial Performance
Metric
DLNG
KPTI
Price
$3.87
$6.30
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$22.17
AVG Volume (30 Days)
54.7K
413.6K
Earning Date
03-05-2026
02-18-2026
Dividend Yield
5.14%
N/A
EPS Growth
30.14
N/A
EPS
1.29
N/A
Revenue
$158,275,000.00
$142,530,000.00
Revenue This Year
N/A
$3.82
Revenue Next Year
$0.37
N/A
P/E Ratio
$3.02
N/A
Revenue Growth
4.34
N/A
52 Week Low
$3.18
$3.51
52 Week High
$5.35
$10.80

Technical Indicators

Market Signals
Indicator
DLNG
KPTI
Relative Strength Index (RSI) 60.55 39.97
Support Level $3.70 $7.05
Resistance Level $4.18 $8.95
Average True Range (ATR) 0.13 0.62
MACD 0.01 -0.18
Stochastic Oscillator 50.00 1.85

Price Performance

Historical Comparison
DLNG
KPTI

About DLNG Dynagas LNG Partners LP

Dynagas LNG Partners LP is a limited partnership company focused on owning and operating high specification and versatile LNG carriers that are employed on multi-year contracts with international energy companies, providing the benefits of stable cash flows and high utilization rates. The company defines charters of two years or more as multi-year charters. Its current LNG Carrier fleet is optimized for trading flexibility. In addition to conventional trade, part of LNG Carrier fleet is assigned with Ice Class 1A FS notation and are winterized which enables trade in subzero and ice bound conditions.

About KPTI Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.

Share on Social Networks: